Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Seres Therapeutics Inc MCRB

Healthcare Biotechnology
Seres Therapeutics, Inc. is a commercial-stage microbiome therapeutics company. It is focused on the development and commercialization of a novel class of biological drugs, which are designed to treat disease by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. Its lead program, VOWST, is to prevent recurrence of... see more

Recent & Breaking News (NDAQ:MCRB)

Seres Therapeutics Announces Topline Results for SER-287 Phase 2b Study in Mild-to-Moderate Ulcerative Colitis

Business Wire July 22, 2021

Seres Therapeutics, Nestlé Health Science Announce SER-109 Co-Commercialization License Agreement

Business Wire July 1, 2021

Dr. Stephen Hahn, 24th US FDA Commissioner and Former Chief Medical Executive at MD Anderson, joins Flagship Pioneering as Chief Medical Officer of Flagship's Preemptive Medicine and Health Security Initiative

PR Newswire June 14, 2021

Seres Therapeutics to Present at JMP Securities Life Sciences Conference

Business Wire June 10, 2021

Seres Therapeutics to Host Virtual Investor Event on June 21, 2021

Business Wire June 10, 2021

 Seres Therapeutics Presents Research from its Early-Stage Microbiome Therapeutic Oncology Programs at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

Business Wire June 4, 2021

Seres Therapeutics Announces FDA Clearance of IND for SER-155, an Investigational Microbiome Therapeutic for the Prevention of Antibiotic-Resistant Bacterial Infections and Graft-versus-Host Disease (GvHD)

Business Wire June 1, 2021

Seres Therapeutics to Present at Upcoming Virtual Investor Conferences

Business Wire May 25, 2021

Invaio Sciences Raises $88.9 Million to Accelerate the Transition to Biological Agriculture

PR Newswire May 25, 2021

Seres Therapeutics Presents Data Across its Broad Microbiome Pipeline Including New 24-Week Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection at Digestive Disease Week 2021

Business Wire May 21, 2021

Seres Therapeutics Announces David Arkowitz to Join as Executive Vice President, Chief Financial Officer and Head of Business Development

Business Wire May 20, 2021

Seres Therapeutics to Present Clinical Research on the Microbiome's Impact on Allogeneic Hematopoietic Stem Cell Transplantation and Cancer Immunotherapy at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

Business Wire May 19, 2021

Invaio Sciences Announces Key Agreement with Fundecitrus in Brazil to Combat Against Citrus Greening

PR Newswire May 19, 2021

Seres Therapeutics to Present at RBC Capital Markets 2021 Global Healthcare Conference

Business Wire May 12, 2021

This is Why a Health Gut is Crucial for Your Wellbeing

Press Releases May 11, 2021

Seres Therapeutics to Present Key Data on Investigational Microbiome Therapeutics for Recurrent C. difficile Infection and Ulcerative Colitis at the Digestive Disease Week (DDW) Annual Meeting

Business Wire May 11, 2021

Seres Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates

Business Wire May 4, 2021

Seres Therapeutics to Host First Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on May 4, 2021

Business Wire April 28, 2021

Seres Therapeutics to Present at Jefferies Microbiome-Based Therapeutics Summit

Business Wire April 15, 2021

Invaio Sciences Strengthens Leadership Team with Appointment of Peleg Chevion as President and Chief Commercial Officer

PR Newswire March 30, 2021